Lydia CaiManaging Director and Head of Healthcare, China at TPG
Lydia Cai is a Managing Director at TPG Capital Asia based in Beijing and leads TPG’s healthcare investments in the Greater China area. Her main healthcare transactions include the take private and SPAC exit transactions of United Family Healthcare (the largest private premium hospital chain in China), the buyout transactions of PPC (a North Asia focused clinical CRO) and Novotech (Australia’s largest independent clinical CRO), a structured minority investment in Kangji Medical (the largest domestic manufacturer of minimally invasive surgical instruments and accessories) and minority investments in Ark Bio and Zhaoke Ophthalmology. She currently serves on the Board of Directors for PPC, Novotech, Kangji Medical and Zhaoke Ophthalmology.
Prior to joining TPG in 2011, Lydia was an Associate at HAO Capital, a China-focused early stage private equity fund focusing on growth-stage healthcare investments. Lydia started her career as a research analyst covering the medical supplies and devices industry at Credit Suisse in New York. Lydia graduated from Yale University with a BA in Biomedical Engineering and Economics.